System Transmission

Top Signal

100#1 JOB

Activity

2191Ripe

+952 today

System

Live1m

Terminal Asset View

stockNASDAQ

PTGX

$92.36-3.21%

Protagonist Therapeutics Inc

Overripe

Market value

24H Total Traded

Total supply

52-Week Range

Ripeness Index

32Overripe

Live Analysis Active

Company Mission

Protagonist Therapeutics Inc creates oral peptide medicines to treat inflammatory diseases such as ulcerative colitis. Doctors and patients use these drugs because they offer a convenient alternative to injections. The company makes money by partnering with larger pharmaceutical firms and advancing its drugs through clinical trials to gain regulatory approval and future sales.

PTG

Industry Context

This company operates in the biotechnology sector, focusing on developing novel treatments for chronic inflammatory conditions. It targets diseases like ulcerative colitis and Crohn's disease, where current options are limited. The industry is competitive, with many firms racing to create more effective and convenient therapies.

Scoring Terminal

Intelligence Pipeline Active

Algorithm Verified

Asset Diagnostics

ProtocolV2.1_TACTICAL

Technical Matrix

Scanning

53Matrix

Market Momentum

54.9— Holding Steady

Trend Strength

75— Active Setup

Momentum Engine

Ready

Velocity Score

StaticOptimal FlowMax Vel

Trading Activity

1.4x— Normal Volume

Today's Change

-3.21%— Live Performance

Social Frequency

Listening

Social Freq

0.0x

Normal Vol

X/Twitter Activity

0.0x— Streaming

Reddit Buzz

0.0x— Synced

System Observation

ANALYSIS:Monitoring pattern stability. Currently scanning for high-confidence technical signals.

Lat14ms

BufOK

Positive Catalysts

No active score modifiers detected

Risk Flags

52W Threshold-1

Price is extended significantly above 52-week highs.

Banana Farmer tracks 100's of signals to synthesize this proprietary score.

0Velocity

Awaiting Data

Social Intelligence Pulse.

Our engine is currently indexing PTGX across global social channels to detect early sentiment shifts and technical alignment.

XMonitoring

RedditMonitoring

WebMonitoring

Social GrowthPending

Signal CoverageInitializing

Signal Catalysts

Intelligence Narrative Connected

Updated 04:49 AM UTC

Develops oral peptide drugs for inflammatory diseases, generating revenue through partnerships and clinical trial successes.

No technical data available, but watch for price breaking above $92 to confirm bullish momentum as industry trends favor biotech innovation.

No volume data available, but monitor if volume spikes 2x average near $92, indicating institutional interest due to potential drug approvals.

Industry trend toward targeted therapies is driving strength, with price holding above $92 support, signaling resilience. Watch for sector recovery in healthcare.

Educational only.

Precision Intelligence Model

Live Terminal Stream

Loading chart...